Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 3/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | YAP1 | P46937 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30008265 | 1.00 | GRIN2B (0.48) | GRIN2BGRIN2CCDK4CNR2BACE1 | |
| SCHEMBL30310450 | 0.97 | GRIN2B (0.46) | GRIN2BGRIN2CCDK4CNR2BACE1 | |
| SCHEMBL24740317 | 0.90 | GRIN2B (0.50) | GRIN2BGRIN2CCDK4CNR2BACE1 | |
| SCHEMBL24113112 | 0.87 | GRIN2B (0.47) | GRIN2BGRIN2CCDK4CNR2JAK3 | |
| SCHEMBL3535138 | 0.82 | GRIN2B (0.57) | GRIN2BGRIN2CCDK4JAK3 | |
| SCHEMBL3533735 | 0.82 | GRIN2B (0.57) | GRIN2BGRIN2CCDK4JAK3 | |
| SCHEMBL3535136 | 0.82 | GRIN2B (0.57) | GRIN2BGRIN2CCDK4JAK3 | |
| SCHEMBL3534085 | 0.82 | GRIN2B (0.57) | GRIN2BGRIN2CCDK4JAK3 | |
| SCHEMBL18121987 | 0.79 | GRIN2B (0.60) | GRIN2BGRIN2CCDK4JAK3TRPV3 | |
| SCHEMBL19852936 | 0.78 | GRIN2B (0.61) | GRIN2BGRIN2CCDK4KDM1AJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | GRIN2B 4555/4885GRIN2C 3506/4885CDK4 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.